Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

about

The nature of the GRE influences the screening for GR-activity enhancing modulators.

P2860

Q38697860-FB7997B4-BF1B-4CAA-A46F-D1CBEAE800B0

P2860

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

Item

http://www.wikidata.org/entity/Q53768454

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

@en

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

@nl

type

Item

label

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

@en

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

@nl

prefLabel

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

@en

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

@nl

P1476

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

@en

P2093

Heiner Schäfer

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.

Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival

Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?

Targeting histone deacetylases in pancreatic ductal adenocarcinoma.

An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.

Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.

Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.

P304

1251-1254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/13543784.2016.1240167

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Arlt

P577

2016-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27666721

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

about

P2860

P2860

Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921